Sanara MedTech Reports Strong Preliminary 2025 Results, Positive 2026 Guidance, and Secures Major Vizient Contract

summarizeSummary

Sanara MedTech Inc. announced strong preliminary financial results for Q4 and full year 2025, provided positive revenue guidance for 2026, and secured a significant Innovative Technology contract with Vizient for its BIASURGE product.

check_boxKey Events

• Preliminary 2025 Financials Reported

  The company reported preliminary Q4 2025 net revenue of $27.2 million to $27.7 million, representing 11% to 13% year-over-year growth excluding a prior-year one-time sales boost. Full year 2025 net revenue is expected to be $102.7 million to $103.2 million, an increase of 21% to 22% year-over-year on an adjusted basis.

• Introduces Positive 2026 Financial Guidance

  Sanara MedTech expects full year 2026 net revenue to range from $116 million to $121 million, indicating growth of approximately 13% to 17% compared to the midpoint of 2025's expected net revenue.

• Secures Major Innovative Technology Contract with Vizient

  The BIASURGE product received an Innovative Technology contract from Vizient, Inc., the nation's largest provider-driven healthcare performance improvement company. This contract significantly expands access to BIASURGE at contracted pricing for Vizient's extensive network of healthcare facility customers, effective January 1, 2026.

• Increased Long-Term Debt

  As of December 31, 2025, the company's long-term debt increased to approximately $46.0 million, up from $30.7 million as of December 31, 2024.

auto_awesomeAnalysis

This 8-K provides a positive outlook for Sanara MedTech, driven by solid preliminary 2025 revenue growth and optimistic 2026 guidance. The most impactful news is the Innovative Technology contract with Vizient, the nation's largest group purchasing organization, which is expected to significantly boost market penetration and sales for the BIASURGE product. While long-term debt increased, the overall financial health appears stable with a slight increase in cash. Investors should view this as a strong signal for continued operational execution and revenue expansion in the surgical solutions market.